Trial Profile
An 8-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study in Hypercholesterolemic Patients to Determine the Efficacy and Safety of Combination Therapy With CI-1027 and a Statin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcabene (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Gemphire Therapeutics; NeuroBo Pharmaceuticals
- 19 Sep 2016 Results published in the Media Release
- 19 Sep 2016 According to a Gemphire Therapeutics media release, data from this study has been published in the Journal of Clinical Lipidology.
- 09 Sep 2016 New trial record